HHS mitigates coronavirus risks, asks for $2.5B in funding

The Trump administration recently asked Congress for $2.5 billion in funding to address the outbreak of the disease as the number of cases continues to grow worldwide.

While the vast majority of the cases are contained to China, where the disease originated in the Wuhan region, coronavirus, or COVID-19, is expected to spread further in the U.S., according to HHS officials who held a press conference on Feb. 25. So far, 53 cases have been confirmed in the U.S., according to the CDC.

“The immediate risk to the American public remains low, but there is now community transmission in a number of countries, including outside of Asia, which is deeply concerning,” HHS Secretary Alex Azar said during a speech to the House Appropriations Committee about the president’s budget.

One AI model puts the spread of disease much higher––2.5 billion infections within 45 days.

HHS says it is working with local, state and private partners to mitigate the spread of the disease. Already the agency has teamed up with at least one drug manufacturer to find therapies to treat the virus and a possible vaccine.

The spread of the disease in China also has the potential to impact drugs in the U.S. due to Chinese reliance on some ingredients used to manufacture medications. While no drugmakers have signaled they expect drug shortages, the FDA is monitoring the medial product supply chain, the agency told CNN Feb. 26.

However, the $2.5 billion request for funds could come from other health resources. Specifically, $136 million of the funds could be transferred from other health programs, The Hill reported.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup